Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer

Molecular Therapy

Volumn 16, Issue 4, 2008, Pages 782-790

  Dai, Shengming ^a   Wei, Dong ^a   Wu, Zhen ^a   Zhou, Xiangyang ^b   Wei, Xiaomou ^a   Huang, Haixin ^a   Li, Guisheng ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b The People Hosptial of Guangxi Zhuang Autonomous Region ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASCITES CELL; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EXOSOME; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; RECTUM CANCER;

EID: 41149172340     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.1     Document Type: Article

References (43)

1. Keller, S, Sanderson, MP, Stoeck, A and Altevogt, P (2006). Exosomes: from biogenesis and secretion to biological function. Immunol Lett 107: 102-108.
2. Théry, C, Zitvogel, L and Amigorena, S (2002). Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
3. Chaput, N, Taïeb, J, Schartz, NE, André, F, Angevin, E and Zitvogel, L (2004). Exosome-based immunotherapy. Cancer Immunol Immunother 53: 234-239.
4. Chaput, N, Flament, C, Viaud, S, Taieb, J, Roux, S, Spatz, A et al. (2006). Dendritic cell derived-exosomes: Biology and clinical implementations. J Leukoc Biol 80: 471-478.
5. Zitvogel, L, Regnault, A, Lozier, A, Wolfers, J, Flament, C, Tenza, D et al. (1998). Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4 594-600.
6. Wolfers, J, Lozler, A, Raposo, G, Regnault, A, Théry, C, Masurier, C et al. (2001). Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303.
7. Théry, C, Boussac, M, Véron, P, Ricciardi-Castagnoli, P, Raposo, G, Garin, J et al. (2001). Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166: 7309-7318.
8. Clayton, A, Court, J, Navabi, H, Adams, M, Mason, MD, Hobot, JA et al. (2001). Analysis of antigen presenting cell derived exosomes, based an immuno-magnetic isolation and flow cytometry. J Immunol Methods 247: 163-174.
9. Kovar, M, Boyman, 0, Shen, X, Hwang, 1, Kohler, R and Sprent, j (2004 Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. Proc Natl Acad Sci USA 103: 11671-11676.
10. Hwang, I, Shen, X and Sprent, J (2003). Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA 100: 6670-6675.
11. Utsugi-Kobukai, S, Fujimaki, 14, Hotta, C, Nakazawa, M and Minami, M (2003). MHC class I-mediated exogenous antigen presentation by exosomes secreted from Immature and mature bone marrow derived dendritic cells. Immunol Lett 89:125-131.
12. Denzer, K, van Eijk, M, Kleijmeer, MJ, Jakobson, E, de Groot, C and Geuze, HJ (2000). Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 165: 1259-1265.
13. + T cells by dendritic cell-derived exosomes. Nat Immunol 3: 1156-1162.
14. André, F, Chaput, N, Schartz, NE, Flament, C, Aubert, N, Bernard, J et al. (2004). Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172: 2126-2136.
15. Chaput, N, Schartz, NE, André, F, Taïeb, J, Novault, S, Bonnaventure, P et al. (2004). Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172 2137-2146.
16. Andre, F, Schartz, NE, Movassagh, M, Flament, C, Pautier, P, Morice, P et al. (2002). Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
17. Bard, MP, Hegmans, JP, Hemmes, A, Luider, TM, Willemsen, R, Severijnen, LA et al. (2004). Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 31 114-121.
18. Navabi, H, Croston, D, Hobot, J, Clayton, A, Zitvogel, L, Jasani, B et al. (2005). Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 35: 149-152.
19. Runz, S, Keller, S, Rupp, C, Stoeck, A, Issa, Y, Koensgen, D et al. (2007). Malignant ascites-derived excisomes of ovarian carcinoma patients contain CD24 and EpCAM Gynecol Oncol 107: 563-571.
20. Escudier, B, Dorval, T, Chaput, N, André, F, Caby, MP, Novault, S et al. (2005). Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. J Transl Med 3: 10.
21. Morse, MA, Garst, J, Osada, T, Khan, S, Hobeika, A, Clay, TM et al. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3: 9.
22. Adams, M, Navabi, H, Croston, D, Coleman, S, Tabi, Z, Clayton, A et al. (2005). The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23: 2374-2378.
23. Segura, E, Nicco, C, Lombard, B, Véron, P, Raposo, G, Batteux, F et al. (2005). ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106: 216-223.
24. Dai, S, Wan, T, Wang, B, Zhou, X, Xiu, F, Chen, T et al. (2005). More efficient induction of HLA-A°0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 11: 7554-7563.
25. Chen, W, Wang, J, Shao, C, Liu, S, Yu, Y, Wang, Q et al. (2006). Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36: 1598-1607.
26. + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med 84: 1067-1076.
27. Xiu, F, Cai, Z, Yang, Y, Wang, X, Wang, J and Cao, X (2007). Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med 85: 511-521.
28. Yang, Y, Xiu, F, Cai, Z, Wang, J, Wang, Q, Fu, Y et al. (2007). Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 133: 389-399.
29. Weber, J, Sondak, VK, Scotland, R, Phillip, R, Wang, F, Rubio, V et al. (2003). Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97: 186-200.
30. Hodge, JW, Chakraborty, M, Kudo-Saito, C, Garnett, CT and Schlom, J (2005). Multiple costimulatory modalities enhance CTL avidity. J Immunol 174: 5994-6004.
31. Ayantunde, AA and Parsons, SL (2007). Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann Oncol 18: 945-949.
32. Clayton, A, Mitchell, JP, Court, J, Mason, MD and Tabi, Z (2007). Human tumor-derived exosomes selectively impair lymphocyte responses to inteleukin-2. Cancer Res 67: 7458-7466.
33. Yu, S, Liu, C, Su, K, Wang, J, Liu, Y, Zhang, L et al. (2007). Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-6875.
34. Valenti, R, Huber, V, Iero, M, Filipazzi, P, Parmiani, G and Rivoltini, L (2007). Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67: 2912-2915.
35. Liu, C, Yu, S, Zinn, K, Wang, J, Zhang, L, Jia, Y et al. (2006). Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 176: 1375-1385.
36. Whiteside, TL (2005). Tumour-derived exosomes or microvesicles: Another mechanism of tumour escape from the host immune system? Br J Cancer 92: 209-211.
37. Markowicz, S and Engleman, EG (1990). Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85: 955-961.
38. Larsen, CP, Ritchie, SC, Hendrix, R, Linsley, PS, Hathcock, KS, Hodes RJ et al. (1994). Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 152: 5208-5219.
39. Ferrome, CR, Perales, MA, Goldberg, SM, Somberg, CJ, Cymerman, DH, Gregor, PD et al. (2006). Adjuvanticity of plasmid DNA encoding cytokine fused to immunoglobulin Fc domains. Clin Cancer Res 12 5511-5519.
40. Chavan, R, Marfatia, KA, An, IC, Garber, DA and Feinberg, MB (2006). Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 80: 7676-7687.
41. Parmiani, G, Castelli, C, Villa, L, Santinami, M, Colombo, MP and Rivoltini, L (2006). Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18: 226-232.
42. Li, J, Bouton-Verville, H, Holmes, LM, Burgin, KE, Jakubchak, S, Yu, X et al. (2004). Inhibition or promotion of tumor growth by granulocyte-macrophage colony stimulating factor derived from engineered tumor cells is dose-dependent. Anticancer Res 24: 2717-2721.
43. de Vries, IJ, Bernsen, MR, Lesterhuis, WJ, Scharenborg, NM, Strijk, SP, Gerritsen, MJ et al. (2005). Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23: 5779-5787.